

Advisory Group on Contraception (AGC): Terms of reference

Objectives

1. The AGC is an expert advisory group made up of leading clinicians and advocacy groups who have come together to discuss and make policy recommendations concerning the contraceptive needs of women of all ages
2. The AGC will work with parliamentarians, policy-makers, advocacy groups and member organisations with an interest in sexual and reproductive health to ensure that the policy environment appropriately addresses the contraceptive needs of post-teen women. The AGC will also raise awareness of issues relevant, or of concern, to the contraceptive community
3. The purpose of the AGC is to ensure NHS and public health services deliver improvements in contraceptive services so that all women have access to high quality services which offer them information about and a choice from the full range of contraceptive options

Structure and activity

4. Incisive Health will act as secretariat to the AGC. This will entail organising meetings of the group, providing strategic policy and communications advice, and supporting members in the implementation of its activities
5. Strategic decisions about the AGC's policy or communications activity will be made by all members, either at member meetings or through e-mail discussion
6. The AGC will hold at least three meetings throughout each calendar year, organised by the secretariat. The secretariat will seek to invite at least two guest speakers to meetings throughout the year
7. No chair for the AGC will be appointed. However, a member may be appointed to act as a spokesperson or representative for the group to external stakeholders (for example at external meetings or for media comment)
8. Dates for AGC meetings during the forthcoming year will be arranged at the end of the previous calendar year. Decisions on dates will be determined on the basis of the majority of members' availability
9. All public materials (including policy briefings, press releases and reports) will be circulated to the AGC via e-mail by the secretariat for comment and approval before publication
10. The secretariat will be expected to provide members with reasonable deadlines for comment on public materials
11. Individual members will be expected to provide comments and feedback on all public materials from the AGC. Where no comments or feedback are received by the secretariat following at least one reminder email or phone call, this will be interpreted as approval from the member
12. Editorial control of all public materials rests with the AGC members alone

Advice

13. The purpose of the AGC is to provide advice and make policy recommendations to external stakeholders about how NHS and public health services can be improved in order to better meet the contraceptive needs of women of all ages
14. External stakeholders include, but are not limited to, Members of Parliament, the Department of Health and Social Care, the Office of Health Improvement and Disparities, the UK Health Security Agency, NHS England, Integrated Care Systems, local authorities, and providers of sexual and reproductive health services
15. The AGC's programme of activity should not seek to duplicate activity being undertaken by external stakeholders or members, but to complement activity. The AGC should seek to engage with external organisations and, where appropriate, identify avenues for collaboration
16. Where opportunities for collaboration with an external stakeholder arise, consent must be reached by members of the AGC for this activity to proceed and a clear project plan, including respective responsibilities, should be agreed upon

Membership

17. New members are admitted following the recommendation of an individual member or the secretariat and agreement is secured from the whole group
18. All members agree to accept the decision-making processes of the AGC, respect the views of other members and do nothing to bring the AGC into disrepute

Finances

19. The meetings and activity of the AGC are funded by Bayer plc, Organon and Pfizer. Bayer plc, Organon and Pfizer provide sponsorship for the benefit of the AGC to pay for the secretariat of the AGC, which is provided by Incisive Health. This will be recorded as a transfer of value to the AGC.
20. Members of the AGC receive no payment from Bayer plc, Organon and Pfizer for attending meetings, except to cover appropriate travel costs
21. All public materials from the AGC will include a declaration of how it is funded

Last updated February 2024